Atopic Dermatitis
Article
Atopic dermatitis: Rapid and sustained disease control with dupilumab
News from the FDA/CDC
FDA approves two JAK-1 inhibitors for moderate to severe atopic dermatitis
“It’s big news because a few years ago we didn’t have any systemic treatments that are safer than the classical immunosuppressants.”
Supplements
Atopic Dermatitis: A supplement to Dermatology News
Latest News
Hand eczema and atopic dermatitis closely linked
“As clinicians, we sometimes need to rule out a few differentials, including psoriasis and T-cell lymphoma,” Dr. Jacob P. Thyssen said.
Conference Coverage
Sorting out sleep complaints in children with AD can be complex
“There’s a loss of about 50 minutes of sleep per night in children with AD,” Dr. Stephen H. Sheldon said.
Conference Coverage
Key questions to ask atopic dermatitis patients with sleep complaints
Assessment tools to consider are the Epworth Sleepiness Scale, the Insomnia Severity Index, and the STOP-Bang questionnaire.
Conference Coverage
Longitudinal course of atopic dermatitis often overlooked, expert says
“Understanding the long-term course may improve our ability to phenotype, prognosticate, and personalize our care,” Dr. Raj Chovatiya said.
Conference Coverage
Itch-dominant atopic dermatitis often flies under the radar
A disconnect often exists between clinician-reported and patient-reported outcome measures, says Dr. Jonathan Silverberg.
Conference Coverage
Atopic dermatitis can be especially burdensome in the elderly
There is good data on higher relative risk of osteoporosis/fractures and dementia specifically among older adults with AD.
News from the FDA/CDC
FDA gives nod to tralokinumab for adults with moderate to severe AD
The drug is expected to be available by February 2022.
Conference Coverage
Does atopic dermatitis pose an increased risk of acquiring COVID-19?